SGLT2 Inhibitors: 4 Points on Efficacy, Safety You Need to Know


Studies looking at add-on treatment with SGLT2 inhibitors show their effects on glycemic control to be roughly additive. Here, a concise look at clinical trial results plus guidance on renal dose adjustment.

The insulin-independent action of the SGLT2 inhibitors makes their use appropriate at most points in the disease progression of T2DM. In clinical trials they have also been shown effective as add-on therapy in patients not achieving A1C goals on monotherapy or dual therapy with existing agents.The slides above summarize the results of the key "combination" studies, provide guidance on dosage adjustment for renal impairment,  and review the primary pros and cons currently known about SGLT2 inhibitors.For the part 1 slide show, "SGLT2 Inhibitors: 5 Things You Should Know," click here.

Related Videos
A panel of 5 experts on Cushing's syndrome
A panel of 5 experts on Cushing's syndrome
Laxmi Mehta, MD | Credit: American Heart Association
Reviewing 2023 with FDA Commissioner Robert M. Califf, MD
Erin Michos, MD | Credit: Johns Hopkins University
© 2024 MJH Life Sciences

All rights reserved.